Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Investing in the specialist workforce and overcoming access barriers is essential to successful delivery of this therapy in the NHS, write Jessie Enakhumhe and Yasmin Sheikh Casgevy, or exagamglogene ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

Three Motley Fool contributors think they've identified magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: ...

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex manufactures CASGEVY, a treatment for sickle-cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). In conjunction with CASGEVY treatments, patients must undergo chemotherapy ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell ...

For the 2025 lecture, Lin presented "Developing Gene and Cell Therapies: Learnings from Casgevy and Visions for the Future." Lin has extensive experience in the development of gene-modified cell ...